Hao Ping

2.4k total citations
72 papers, 1.2k citations indexed

About

Hao Ping is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Hao Ping has authored 72 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pulmonary and Respiratory Medicine, 25 papers in Molecular Biology and 12 papers in Oncology. Recurrent topics in Hao Ping's work include Prostate Cancer Treatment and Research (10 papers), Prostate Cancer Diagnosis and Treatment (9 papers) and Cancer-related molecular mechanisms research (7 papers). Hao Ping is often cited by papers focused on Prostate Cancer Treatment and Research (10 papers), Prostate Cancer Diagnosis and Treatment (9 papers) and Cancer-related molecular mechanisms research (7 papers). Hao Ping collaborates with scholars based in China, United States and Australia. Hao Ping's co-authors include Nianzeng Xing, Brian M. Freed, Feiya Yang, Barbara E. Bierer, Yanli Ouyang, Michael T. Aubrey, Xinxing Lu, Dong Chen, Qinxin Zhao and Dexi Chen and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Biochemical and Biophysical Research Communications.

In The Last Decade

Hao Ping

67 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hao Ping China 19 438 305 195 158 151 72 1.2k
Tomohiro Matsuo Japan 20 352 0.8× 227 0.7× 161 0.8× 158 1.0× 230 1.5× 130 1.2k
Hsin‐Chih Yeh Taiwan 23 528 1.2× 308 1.0× 206 1.1× 241 1.5× 411 2.7× 110 1.4k
Mariangela Mancini Italy 20 503 1.1× 314 1.0× 154 0.8× 163 1.0× 378 2.5× 50 1.3k
He-He Hu China 11 554 1.3× 273 0.9× 128 0.7× 112 0.7× 156 1.0× 14 1.3k
Weizhen Wu China 21 603 1.4× 175 0.6× 260 1.3× 85 0.5× 339 2.2× 49 1.4k
Chung‐Sheng Shi Taiwan 25 703 1.6× 228 0.7× 223 1.1× 315 2.0× 222 1.5× 71 1.7k
Ting Rao China 20 595 1.4× 323 1.1× 267 1.4× 101 0.6× 126 0.8× 73 1.2k
Xi Yu China 23 547 1.2× 202 0.7× 243 1.2× 265 1.7× 155 1.0× 64 1.4k
Weiming Wang China 25 755 1.7× 311 1.0× 189 1.0× 122 0.8× 138 0.9× 99 2.1k
Tongyu Zhu China 20 426 1.0× 147 0.5× 92 0.5× 100 0.6× 251 1.7× 77 1.3k

Countries citing papers authored by Hao Ping

Since Specialization
Citations

This map shows the geographic impact of Hao Ping's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hao Ping with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hao Ping more than expected).

Fields of papers citing papers by Hao Ping

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hao Ping. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hao Ping. The network helps show where Hao Ping may publish in the future.

Co-authorship network of co-authors of Hao Ping

This figure shows the co-authorship network connecting the top 25 collaborators of Hao Ping. A scholar is included among the top collaborators of Hao Ping based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hao Ping. Hao Ping is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Ji, John S., Haowen Wang, Hari S. Iyer, et al.. (2025). Long-term green space exposure associated with lower mortality in prostate cancer survivors: a retrospective cohort study using SEER from 1995 to 2019. Environment International. 204. 109812–109812.
3.
Zhang, Jian, et al.. (2025). Remaining Useful Life Prediction Method for Highway Electromechanical Equipment Based on Bayesian Algorithm-Optimized CNN-LSTM Model. SAE technical papers on CD-ROM/SAE technical paper series. 1.
4.
Zhang, Yishan, et al.. (2024). Treatment Options for Signet Ring Cell Carcinoma of the Urinary Bladder: A Population-Based Study. Cancer Control. 31. 2925696533–2925696533. 2 indexed citations
5.
Zeng, Hongmei, Sergiusz Nawrocki, Jakub Morze, et al.. (2023). Racial/ethnic disparities in the cause of death among patients with prostate cancer in the United States from 1995 to 2019: a population-based retrospective cohort study. EClinicalMedicine. 62. 102138–102138. 17 indexed citations
6.
Ping, Hao, et al.. (2023). RNA-Sequencing Analysis Indicates That N-Cadherin Promotes Prostate Cancer Progression by the Epigenetic Modification of Key Genes. DNA and Cell Biology. 42(9). 563–577. 4 indexed citations
7.
Peng, Xiang, Zhen Du, Mingdong Wang, et al.. (2022). RNA sequencing and integrative analysis reveal pathways and hub genes associated with TGFβ1 stimulation on prostatic stromal cells. Frontiers in Genetics. 13. 919103–919103. 2 indexed citations
8.
Peng, Xiang, Di Guan, Zhen Du, et al.. (2021). Efficacy and safety of prostatic artery embolization for benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials. European Radiology. 31(7). 4929–4946. 26 indexed citations
9.
Lu, Xinxing, Feiya Yang, Dexi Chen, et al.. (2020). Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways. International Journal of Biological Sciences. 16(7). 1121–1134. 155 indexed citations
11.
Xing, Nianzeng, Qiang Fu, Feiya Yang, et al.. (2019). Feasibility of prostatectomy without prostate biopsy in the era of new imaging technology and minimally invasive techniques. World Journal of Clinical Cases. 7(12). 1403–1409. 8 indexed citations
12.
Ping, Hao, et al.. (2016). IKK inhibitor suppresses epithelial-mesenchymal transition and induces cell death in prostate cancer. Oncology Reports. 36(3). 1658–1664. 15 indexed citations
13.
Xu, Jianqiang, et al.. (2015). Claudin 8 Contributes to Malignant Proliferation in Human Osteosarcoma U2OS Cells. Cancer Biotherapy and Radiopharmaceuticals. 30(9). 400–404. 12 indexed citations
14.
Li, Zhongjun, et al.. (2014). ALDH Maintains the Stemness of Lung Adenoma Stem Cells by Suppressing the Notch/CDK2/CCNE Pathway. PLoS ONE. 9(3). e92669–e92669. 25 indexed citations
16.
Zhang, Weibin, et al.. (2012). The outcome of surgical treatment for recurrent giant cell tumor in the appendicular skeleton. Journal of Orthopaedic Science. 17(4). 464–469. 6 indexed citations
17.
Sun, Jianguo, Rongxia Liao, Jun Qiu, et al.. (2010). Microarray-based analysis of microRNA expression in breast cancer stem cells. Journal of Experimental & Clinical Cancer Research. 29(1). 174–174. 25 indexed citations
18.
Li, Guanghui, Donglin Wang, Yide Hu, et al.. (2009). Berberine inhibits acute radiation intestinal syndrome in human with abdomen radiotherapy. Medical Oncology. 27(3). 919–925. 44 indexed citations
19.
Ping, Hao, et al.. (2006). Immunohistochemical analysis of Omi/HtrA2 expression in prostate cancer and benign prostatic hyperplasia. Apmis. 114(12). 893–898. 14 indexed citations
20.
Ping, Hao, et al.. (2004). Expression and implication of hypoxia inducible factor-1α in prostate neoplasm. Current Medical Science. 24(6). 593–595. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026